Barclays says Sarepta’s (SRPT) debt refinancing was done on largely favorable terms and has minimized the company’s liquidity concerns. Barclays continues to focus on the Elevidys launch in the second half of 2025 as well as regulatory updates. It keeps an Equal Weight rating on Sarepta with a $22 price target The stock in late morning trading is down 5% to $19.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- BofA trims Sarepta price target, says debt refinancing mitigates liquidity risk
- Sarepta refinances $700M of convertible notes, extends maturities to 2030
- Sarepta Therapeutics Restructures Debt with New Convertible Notes
- Sarepta Therapeutics Faces Regulatory Challenges and Potential Share Price Decline
- Citi says FDA may take ‘more comprehensive look’ at Sarepta Elevidys adjustment